Literature DB >> 9472886

Natural history of stenosis from intracranial atherosclerosis by serial angiography.

P T Akins1, T K Pilgram, D T Cross, C J Moran.   

Abstract

BACKGROUND AND
PURPOSE: Knowledge of the natural history of stenoses due to intracranial atherosclerosis may be useful for evaluating possible treatments such as angioplasty.
METHODS: We retrospectively reviewed records over a 7-year period to identify patients with intracranial atherosclerotic stenoses and serial angiograms. Quantitative measurements of stenoses were made in a blinded manner, and clinical outcomes were reviewed.
RESULTS: We identified 21 patients with 45 intracranial stenoses who underwent repeat angiography at an average interval of 26.7 months. The average stenosis for all intracranial lesions was 43.9% initially and 51.8% on follow-up (P=.032). The average stenosis in the intracranial internal carotid artery (ICA) was stable (51.2% versus 52.6%). The average stenosis in the anterior cerebral artery (ACA), middle cerebral artery (MCA), and posterior cerebral artery (PCA) progressed from 32.4% to 49.7% (P=.037). Based on a minimum 10% change, 20% of intracranial ICA lesions progressed compared with 61% of ACA, MCA, and PCA lesions. Regression occurred in 14% of the intracranial ICA group and 28% of the ACA-MCA-PCA group. Cerebrovascular events were infrequent during this period, with 4 transient ischemic attacks and 1 intracerebral hemorrhage.
CONCLUSIONS: Intracranial atherosclerotic stenoses are dynamic lesions demonstrating both progression and regression.

Entities:  

Mesh:

Year:  1998        PMID: 9472886     DOI: 10.1161/01.str.29.2.433

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  28 in total

Review 1.  [Stents in the treatment of intracranial atherosclerotic stenoses].

Authors:  R du Mesnil de Rochemont; M Sitzer; F E Zanella; J Berkefeld
Journal:  Radiologe       Date:  2004-10       Impact factor: 0.635

2.  Anterior cerebral artery angioplasty for intracranial atherosclerosis.

Authors:  Nazli Janjua; Afshin A Divani; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2008-01

Review 3.  [Endovascular treatment for intracranial stenoses. A common statement by neurologists and neuroradiologists].

Authors:  J Berkefeld; G F Hamann; R du Mesnil; W Kurre; H Steinmetz; F E Zanella; M Sitzer
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

4.  Transcranial color-coded sonography successfully visualizes all intracranial parts of the internal carotid artery using the combined transtemporal axial and coronal approach.

Authors:  J Eggers; O Pade; A Rogge; S J Schreiber; J M Valdueza
Journal:  AJNR Am J Neuroradiol       Date:  2009-06-04       Impact factor: 3.825

5.  Angioplasty and stent placement in intracranial atherosclerotic stenoses and dissections.

Authors:  Pedro Lylyk; José E Cohen; Rosana Ceratto; Angel Ferrario; Carlos Miranda
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 6.  MR angiography and imaging for the evaluation of middle cerebral artery atherosclerotic disease.

Authors:  A J Degnan; G Gallagher; Z Teng; J Lu; Q Liu; J H Gillard
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-22       Impact factor: 3.825

7.  Vertebral and intracranial artery angioplasty.

Authors:  J Stephen Jenkins; Rajesh Subramanian
Journal:  Ochsner J       Date:  2003

8.  Prevalence and risk factors of intracranial atherosclerosis in an asymptomatic korean population.

Authors:  Kwang-Yeol Park; Chin-Sang Chung; Kwang Ho Lee; Gyoeng-Moon Kim; Yong-Bum Kim; Kyungmi Oh
Journal:  J Clin Neurol       Date:  2006-03-20       Impact factor: 3.077

9.  Intracranial atherosclerosis: incidence, diagnosis and treatment.

Authors:  Jong S Kim; Dong-Wha Kang; Sun U Kwon
Journal:  J Clin Neurol       Date:  2005-04-30       Impact factor: 3.077

10.  Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.

Authors:  Teng-Yeow Tan; Yeh-Lin Kuo; Wei-Che Lin; Ting-Yao Chen
Journal:  J Neurol       Date:  2009-03-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.